Literature DB >> 24388547

Febuxostat contributes to improvement of endothelial dysfunction in an experimental model of streptozocin-induced diabetic rats.

Seung Joon Hwang1, Kyung Hye Lee1, Hyun Hee Jang1, So Ra Lee1, Jong Shin Woo1, Hong Ju Lee2, Kyung Hwan Jung2, Weon Kim3.   

Abstract

Entities:  

Keywords:  Endothelial dysfunction; Nitric oxide; Xanthine oxidase

Mesh：

Substances：

Year:  2013        PMID： 24388547     DOI： 10.1016/j.ijcard.2013.12.023

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  12 in total

1.  Effect of febuxostat on oxidative stress in hemodialysis patients with endothelial dysfunction: a randomized, placebo-controlled, double-blinded study.

Authors:  Mona Alshahawey; Sara M Shaheen; Tamer Elsaid; Nagwa Ali Sabri
Journal:  Int Urol Nephrol       Date:  2019-08-01       Impact factor: 2.370

2.  Febuxostat Inhibits MPP+-Induced Inflammatory Response Through Inhibiting the JNK/NF-κB Pathway in Astrocytes.

Authors:  Weiwei Yan; Yun Zhang; Li Hu; Qi Li; Hongmei Zhou
Journal:  Neurotox Res       Date:  2021-01-14       Impact factor: 3.911

3.  Febuxostat protects rats against lipopolysaccharide-induced lung inflammation in a dose-dependent manner.

Authors:  Alaa N A Fahmi; George S G Shehatou; Abdelhadi M Shebl; Hatem A Salem
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-12-28       Impact factor: 3.000

4.  Febuxostat mitigates IL-18-induced inflammatory response and reduction of extracellular matrix gene.

Authors:  Qin Geng; Hongju Zhang; Yanhui Cui; Qiaofeng Wei; Shujun Wang
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

Review 5.  Uric acid and progression of chronic kidney disease.

Authors:  Donald J Weaver
Journal:  Pediatr Nephrol       Date:  2018-06-21       Impact factor: 3.714

6.  Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury.

Authors:  Alaa N A Fahmi; George S G Shehatou; Abdelhadi M Shebl; Hatem A Salem
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-05-23       Impact factor: 3.000

7.  Febuxostat improves outcome in a rat model of cancer cachexia.

Authors:  Masaaki Konishi; Loes Pelgrim; Anika Tschirner; Anna Baumgarten; Stephan von Haehling; Sandra Palus; Wolfram Doehner; Stefan D Anker; Jochen Springer
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-04-21       Impact factor: 12.910

8.  Comparison of the Renoprotective Effect of Febuxostat for the Treatment of Hyperuricemia between Patients with and without Type 2 Diabetes Mellitus: A Retrospective Observational Study.

Authors:  Hiroyuki Ito; Shinichi Antoku; Mariko Abe; Takashi Omoto; Masahiro Shinozaki; Shinya Nishio; Mizuo Mifune; Michiko Togane; Masaya Nakata; Tatsuya Yamashita
Journal:  Intern Med       Date:  2016-11-15       Impact factor: 1.271

Review 9.  The role of uric acid in kidney fibrosis: experimental evidences for the causal relationship.

Authors:  Il Young Kim; Dong Won Lee; Soo Bong Lee; Ihm Soo Kwak
Journal:  Biomed Res Int       Date:  2014-05-05       Impact factor: 3.411

10.  Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.

Authors:  Lhanoo Gunawardhana; Lachy McLean; Henry A Punzi; Barbara Hunt; Robert N Palmer; Andrew Whelton; Daniel I Feig
Journal:  J Am Heart Assoc       Date:  2017-11-04       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.